-
India's Sindhu backs monkey measures as badminton worlds set to open
-
Hurricane Lala brushes past Hawaii's Big Island, bringing heavy rain
-
Mass drone attack on Moscow as Russian strikes kill three in Ukraine
-
'Something we dreamed of': Bangladesh celebrates historic cricket win
-
Djokovic feels the heat in Cincinnati defeat, Zverev wins all-nighter
-
Rain holds up India on day two of Sri Lanka Test
-
Pallister stuns Ledecky in Pan Pacs 800m free as two world records carry Douglass to gold
-
The Ukrainian social media channels tracking Russian missiles
-
Rampant Bangladesh make history with first-ever Test win in Australia
-
Disney offers fans an escapist bubble at D23 event
-
UK's media-savvy PM Burnham shifts messaging to TikTok, podcasts
-
Thousands await aid after deadly Indonesian quake
-
Gay badminton star Gilmour urges progress on LGBTQ rights in Asia
-
Chinese ship sets off for Europe through Arctic, halving travel time
-
Pallister takes down Ledecky in Pan Pacs 800m freestyle
-
Bangladesh on verge of historic win in Australia as Mehidy takes five
-
Douglass breaks 50m free world record again to claim Pan Pacs gold
-
Messi sees penalty saved as Nashville routs Inter Miami in MLS
-
As Opel turns to Chinese partners, its hometown frets about the future
-
Heat is on as German winegrowers struggle to protect vines
-
Mehidy takes three as Bangladesh close on historic win in Australia
-
Hope fades for finding survivors of Colombia quake as rescued woman dies
-
Hope fades for finding surivivors of Colombia quake as rescued woman dies
-
Japan aims for the moons of Mars
-
Hurricane Lala dumps heavy rain on Hawaii
-
'People could get hurt': Conservationists decry AI wildlife visuals
-
Jaded voters, same old choices: Brazil kicks off election campaign
-
'Another chance to live': Flores residents recall quake panic
-
'Everyone lives in fear': Yemenis worry about return to all-out war
-
Rivers among nine inducted into Basketball Hall of Fame
-
Cardinals' Baez bashes record three homers in MLB debut
-
No.1 Scheffler leads by two at PGA St. Jude playoff event
-
Djokovic feels the heat in Cincinnati opening defeat
-
Rennie confident Jordan, Roigard will be fit to face Springboks
-
Hunt bags third Euro gold, Diaz shines in triple jump
-
PSG sign Belgian winger Godts from Ajax
-
Depleted Djokovic falls in Cincinnati Masters opener
-
Nillessen claims shock European 1,500m gold
-
Lala, now a hurricane, dumps heavy rain on Hawaii
-
Taylor scores two tries in winning debut as New Zealand captain
-
American Kate Douglass reclaims 50m freestyle world record
-
England defender Spence leaves Spurs for Inter Milan
-
Kit confusion disrupts Newcastle friendly against Leverkusen
-
Moore double leads Spurs to 3-0 friendly win over Hoffenheim
-
Marchand wins first Euros gold as Liebmann breaks 1500m free world record
-
Man Utd beaten by former boss Amorim's AC Milan in friendly finale
-
Zambia's vote marred by intimidation, counting pause: observers
-
Villagers evacuate as Belgium battles record wildfire
-
Marchand wins 200m butterfly for first Euros gold
-
Despite booming economy, young Moroccans still dream of Europe
US panel weighs authorizing Covid vaccines for youngest children
After months of anxious wait for some parents, a panel of experts convened by the US Food and Drug Administration will meet Wednesday to weigh recommending Covid vaccines for the nation's youngest children.
Children under five are the only age group not yet eligible for Covid immunization in the United States and most other countries. If, as expected, panelists vote in favor of greenlighting the Pfizer and Moderna vaccines, formal authorizations should follow quickly, with the first shots in arms expected by next week.
Ahead of the meeting, the FDA posted its independent analyses of the two drugs, deeming both safe and effective. It also said there was a pressing unmet need to inoculate children in the age group since their rates of hospitalization and death "are higher than among children and adolescents 5-17 years of age."
Both vaccines are based on messenger RNA technology, which delivers genetic code for the coronavirus spike protein to human cells, training the immune system to be ready for when it encounters the real virus.
Pfizer is seeking authorization for three doses at three micrograms given to ages six months through four years, while Moderna has asked for the FDA to approve its vaccine as two doses of a higher 30 micrograms, for ages six months through five years.
They were tested in trials of thousands of children where they were found to have similar levels of mild effects to older age groups and triggered similar levels of antibodies.
Efficacy against infection was higher for Pfizer, with the company placing it at 80 percent compared to Moderna's estimates of 51 percent in the six-month-old to age two group and 37 percent in the two to five years age group.
But the figures are provisional and Moderna is studying adding a third dose later that may increase its figures.
There are some 20 million US children aged four years and under. If the FDA-appointed experts recommend the two vaccines, then the matter will go to another committee convened by the Centers for Disease Control and Prevention for a final say.
White House officials last week said the rollout of millions of shots at pharmacies and doctors' offices could begin as soon as June 21, following the Juneteenth holiday on June 20.
Of the total US Covid deaths, 480 have come in children under five, according to the latest official data.
Obesity, neurological disorders and asthma are associated with increased risk of severe disease, "however, a majority of children hospitalized for Covid-19 have no underlying medical conditions," the FDA said in a document.
Children can also go on to contract multisystem inflammatory syndrome in children (MIS-C), a rare but serious post-viral condition.
Data on long Covid in children is sparse, but the FDA's document cited a national survey in the United Kingdom which found that "among children ages two to 11 years who tested positive for COVID-19, 7.2 percent reported continued symptoms at 12 weeks."
L.Durand--AMWN